Shots: The US FDA has granted approval to Mavyret for shortening the treatment duration from 12 to 8wks. in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes […]readmore
Shots: The marketing authorization is based on P-IIIb EXPEDITION-8 study assessing Maviret in 280 treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks. The P-IIIb […]readmore
Shots: Generic of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) will be launched at a list price of $24,000 for common course of therapy and will be available […]readmore
Copyright © 2020 Digiqole. All Right Reserved.